The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives
- 1 May 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 8 (5), 1008-1014
- https://doi.org/10.1158/1535-7163.mct-08-0706
Abstract
Because camptothecins are effective against previously resistant tumors and are the only class of topoisomerase I (Top1) inhibitors approved for cancer treatment, we developed the indenoisoquinolines. Like camptothecins, the indenoisoquinolines selectively trap Top1-DNA cleavage complexes and have been cocrystallized with the Top1-DNA cleavage complexes. Indenoisoquinolines show antitumor activity in animal models. They have several advantages over the camptothecins: (a) They are synthetic and chemically stable. (b) The Top1 cleavage sites trapped by the indenoisoquinolines have different genomic locations, implying differential targeting of cancer cell genomes. (c) The Top1 cleavage complexes trapped by indenoisoquinolines are more stable, indicative of prolonged drug action. (d) They are seldom or not used as substrates for the multidrug resistance efflux pumps (ABCG2 and MDR-1). Among the >400 indenoisoquinolines synthesized and evaluated, three have been retained as leads for clinical development by the National Cancer Institute: NSC 706744, NSC 725776 (Indimitecan), and NSC 724998 (Indotecan). The trapping of Top1 cleavage complexes by indenoisoquinolines in cells results in the rapid and sustained phosphorylation of histone H2AX (γ-H2AX). We discuss the use of γ-H2AX as a pharmacodynamic biomarker for the clinical development of the indenoisoquinolines. [Mol Cancer Ther 2009;8(5):1008–14]Keywords
This publication has 64 references indexed in Scilit:
- The Binding Orientation of a Norindenoisoquinoline in the Topoisomerase I−DNA Cleavage Complex Is Primarily Governed by π−π Stacking InteractionsThe Journal of Physical Chemistry B, 2008
- Mutations in topoisomerase I as a self-resistance mechanism coevolved with the production of the anticancer alkaloid camptothecin in plantsProceedings of the National Academy of Sciences of the United States of America, 2008
- Investigation of the Lactam Side Chain Length Necessary for Optimal Indenoisoquinoline Topoisomerase I Inhibition and Cytotoxicity in Human Cancer Cell CulturesJournal of Medicinal Chemistry, 2007
- A Systematic Study of Nitrated Indenoisoquinolines Reveals a Potent Topoisomerase I InhibitorJournal of Medicinal Chemistry, 2006
- Synthesis and Evaluation of Indenoisoquinoline Topoisomerase I Inhibitors Substituted with Nitrogen HeterocyclesJournal of Medicinal Chemistry, 2006
- Dihydroindenoisoquinolines function as prodrugs of indenoisoquinolinesBioorganic & Medicinal Chemistry Letters, 2005
- Activation of the DNA damage checkpoint and genomic instability in human precancerous lesionsNature, 2005
- Cellular Topoisomerase I Inhibition and Antiproliferative Activity by MJ-III-65 (NSC 706744), an Indenoisoquinoline Topoisomerase I PoisonMolecular Pharmacology, 2004
- Mechanisms of Camptothecin Resistance by Human Topoisomerase I MutationsJournal of Molecular Biology, 2004
- DNA Damage Induced by DNA Topoisomerase I- and Topoisomerase II- Inhibitors Detected by Histone H2AXphosphorylation in Relation to the Cell Cycle Phase and ApoptosisCell Cycle, 2003